CM
ENGNW icon

Caption Management’s enGene Therapeutics Warrants ENGNW Stock Holding History

Caption Management’s Portfolio ENGNW Stock Details ENGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$96.7K Buy
+333,675
New +$347K ﹤0.01% 1524
2026
Q1 		– Sell
-141,904
Closed -$420K – 1678
2025
Q4 		$420K Buy
141,904
+134,760
+1,886% +$308K ﹤0.01% 1269
2025
Q3 		$5.07K Buy
+7,144
New +$5.41K ﹤0.01% 1596

Other funds holding ENGNW

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Caption Management's ENGNW Position: Q2 2026 in Review

Caption Management opened a new position in enGene Therapeutics Warrants (ENGNW) in Q2 2026: 333,675 shares worth $96.7K. The stake represents ﹤0.01% of the portfolio and ranks #1524 among its holdings. This is a return to the name: Caption Management previously reported a position in ENGNW as recently as Q4 2025.

Caption Management first reported a position in ENGNW in Q3 2025 and has held it in 3 quarters since. The position peaked at $420K in Q4 2025. 11 funds tracked by Wall St. Rank hold ENGNW as of Q2 2026.

  • Caption Management held 333,675 shares of enGene Therapeutics Warrants worth $96.7K as of Q2 2026.
  • enGene Therapeutics Warrants was a new Caption Management position in Q2 2026.
  • enGene Therapeutics Warrants made up ﹤0.01% of Caption Management's portfolio in Q2 2026, its #1524 holding.
  • Caption Management first reported a position in enGene Therapeutics Warrants in Q3 2025 and has held it in 3 quarters since.
  • Caption Management's enGene Therapeutics Warrants position peaked at $420K in Q4 2025.
  • 11 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.